Backgrounds: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is closely related to disease mortality. Systemic inflammation is considered to be involved in the pathogenesis of AECOPD. The current study aimed to investigate the clinical significance of the classic chemokine interleukin (IL)-8 in serum during AECOPD. Materials and Methods: In this current cross sectional, observational study, 50 patients with AECOPD, 25 patients with stable COPD and 25 healthy nonsmokers as the control group were selected. Clinical characteristics and spirometry data were collected. All patients were classified as grade 1-4 based on forced expiratory volume in 1 second (FEV1) after bronchodilation according to the GOLD severity classification and were divided into frequent exacerbation (FE) group (≥2 times/year) and non-frequent exacerbation (NFE) group (<1 time/year) according to acute exacerbation (AE) times in the previous 12 months before the visit. The serum IL-8, IL-6, tumor necrosis factor (TNF)-α, and superoxide dismutase levels were measured by the enzyme-linked immunosorbent assay technique. Results: Serum IL-8 levels increased sequentially from controls [9.45 pg/mL (ranged: 6.85-38.4)], to stable [51.60 pg/mL (ranged: 22.4-131.1)], and exacerbation stage [129 pg/mL (ranged: 57.7-374)]. The level of serum IL-8 was significant higher in patients with FE than that of patients with NFE (209.0 pg/mL (ranged: 115-472) vs 65.6 pg/mL (ranged: 11.2-149.3), P=0.008). A receiver operating characteristics curve (ROC) generated to evaluate IL-8, IL-6, and TNF-α levels to discriminate between patients with and without exacerbation showed that the total area under the curve (AUC) was 0.71 (95% confidence interval (CI): 0.5764-0.8381; P=0.003), 0.54 (95%CI: 0.4048-0.6943; P=0.54), and 0.52 (95%CI: 0.3912-0.6656; P= 0.7). Conclusion: Serum IL-8 is a sensitive, easy-to-measure, and inexpensive biomarker to give an indication of the course of COPD during exacerbation, and is a target to be explored further as a predictor to distinguish the patients prone to exacerbation.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is characterized by recurrent episodes of exacerbations defined as an acute worsening in the severity of patient's symptoms, including dyspnea and coughing that warrants a change in medication or medical intervention. Acute exacerbations (AECOPD) are linked to disease-associated morbidity and mortality, placing significant strains on medical facilities, increasing resource burden, and driving up ongoing health care costs.
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The mechanism of AECOPD is not elucidated comprehensively yet. AECOPD is considered as a kind of systemic inflammation besides the local airway inflammatory disease. The inflammation exaggeration induced by various pathogens or triggers was considered in the AECOPD, partly due to the"spillover" of such local inflammatory processes or the severity of the systemic inflammation itself (1) 
MATERIALS AND METHODS

Study design
In the current cross sectional, observational study, a total of 50 patients with AECOPD and 25 patients with stable COPD were selected from the patients admitted to Smoking history was defined using pack-years.
Exacerbations were defined as increase in any or all of the three major symptoms (dyspnea, sputum volume, and sputum color) from day to day routine in accordance with the definition of Burge and Wedzicha (9) . All patients with AECOPD were classified based on GOLD severity classification as 1(≥80%), 2 (≥50% and <80), 3(≥30% and <50), and 4(<30%) grades according to the predicted FEV1 after bronchial dilation of each patient and were divided into frequent exacerbation (FE) (≥2 times) and non- 
Statistical analysis
All data were analyzed using Graphpad Prism 5.0 or 
RESULTS
Clinical characteristics
Totally, 100 male subjects including 50 patients with exacerbation of COPD, 25 patients with clinically stable COPD, and 25 healthy controls were included in the study.
Their baseline characteristics are shown in Table 1 The data were largely driven by differences in serum IL-8 levels between the controls and patients with COPD exacerbation (P <0.0001). IL-6 levels were 2.04 (ranged: 2.0- 2.14-7.17) in patients with FE and 5.05 pg/mL (ranged: 2.7-10.14) in patients with NFE, with no significant differences between the groups. The level of serum TNF-α was 8.76 pg/mL (ranged: 6.39-14.35) in patients with FE and 8.88 pg/mL (ranged: 6-13.1) in patients with NFE, with no significant differences between the groups (Figure 3 ).
Variables associated with serum IL-8 in AECOPD
In patients with AECOPD, significant correlations were observed between serum IL-8 and blood eosinophil counts, blood eosinophil percentage, the change rate of predicted FEV1, DLCO, and SOD levels in Table 2 . The current study does not allow any conclusions whether or not the relationship between IL-8 and the studied parameters was causal; however, it encourages further mechanistic studies to better understand the issue.
According to the results of the current study, it can be concluded that serum IL-8 can be a sensitive, easy-tomeasure, and inexpensive biomarker to give an indication of the course of COPD during an exacerbation; and it is a target to be explored further as a predictor to distinguish the patients with COPD prone to exacerbation to implement individualized treatment and improve the disease outcome.
